CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance
The emergence of new infections in India is a growing concern
The emergence of new infections in India is a growing concern
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
This two-day program was attended by 40 doctors & paramedical staff
Becomes the first rehab & recovery center in east India to earn NABH accreditation
Subscribe To Our Newsletter & Stay Updated